MannKind Corporation (MNKD) Mergers and Acquisition Call Transcript

MannKind Corporation (NASDAQ:MNKD) Mergers and Acquisition Conference Call August 25, 2025 8:30 AM ET

Company Participants

Christopher B. Prentiss – Chief Financial Officer
Michael E. Castagna – CEO & Director

Conference Call Participants

Brandon Richard Folkes – H.C. Wainwright & Co, LLC, Research Division
Olivia Simone Brayer – Cantor Fitzgerald & Co., Research Division
Tiago Felipe Fauth – Wells Fargo Securities, LLC, Research Division
Yun Zhong – Wedbush Securities Inc., Research Division

Operator

Good morning, and welcome to the MannKind Corporation’s call to discuss its acquisition of scPharmaceuticals. The call will be available for playback on the MannKind Corporation website shortly after the conclusion of this call and will be available for approximately 90 days.

During the course of this call, management may make certain forward-looking statements regarding future events and the company’s future performance, including statements about the proposed acquisition of scPharmaceuticals, the expected timing thereof, and the expected benefits therefrom, MannKind’s and scPharmaceuticals products and product candidates, including the ongoing and planned clinical trials, potential benefits and market opportunity thereof, and other statements that are not historical facts. These forward- looking statements reflect MannKind’s current perspective on existing trends and information.

Any such forward-looking statements do not guarantee future performance and involve risks and uncertainties including those noted in the Risk Factors section of MannKind’s and scPharmaceuticals’ latest SEC filings. Actual results may differ materially from those projected in these forward-looking statements.

For the benefit of those listening to the replay, this call is being held and recorded on August 25, 2025. Since then, MannKind and scPharmaceuticals may have made additional announcements related to the topics discussed. Please reference MannKind’s and scPharmaceuticals’ most recent press releases and current filings with the SEC. MannKind and scPharmaceuticals decline any obligation to update these forward-looking statements except as required by applicable securities laws.